Annual EBITDA:
-$154.53M+$340.60M(+68.79%)Summary
- As of today, APLS annual EBITDA is -$154.53 million, with the most recent change of +$340.60 million (+68.79%) on December 31, 2024.
- During the last 3 years, APLS annual EBITDA has risen by +$576.74 million (+78.87%).
- APLS annual EBITDA is now -3740.83% below its all-time high of -$4.02 million, reached on December 31, 2013.
Performance
APLS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$32.84M+$50.04M(+60.38%)Summary
- As of today, APLS quarterly EBITDA is -$32.84 million, with the most recent change of +$50.04 million (+60.38%) on June 30, 2025.
- Over the past year, APLS quarterly EBITDA has dropped by -$3.85 million (-13.26%).
- APLS quarterly EBITDA is now -125.18% below its all-time high of $130.40 million, reached on December 31, 2020.
Performance
APLS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$188.26M-$3.85M(-2.09%)Summary
- As of today, APLS TTM EBITDA is -$188.26 million, with the most recent change of -$3.85 million (-2.09%) on June 30, 2025.
- Over the past year, APLS TTM EBITDA has increased by +$123.08 million (+39.53%).
- APLS TTM EBITDA is now -6958.94% below its all-time high of -$2.67 million, reached on September 30, 2014.
Performance
APLS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
APLS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +68.8% | -13.3% | +39.5% |
| 3Y3 Years | +78.9% | +77.8% | +61.9% |
| 5Y5 Years | +48.3% | +71.5% | +58.1% |
APLS EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +78.9% | -27.7% | +81.2% | -15.4% | +70.5% |
| 5Y | 5-Year | at high | +78.9% | -125.2% | +83.1% | -15.4% | +70.5% |
| All-Time | All-Time | -3740.8% | +78.9% | -125.2% | +83.1% | -6958.9% | +70.5% |
APLS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$32.84M(+60.4%) | -$188.26M(-2.1%) |
| Mar 2025 | - | -$82.88M(-222.3%) | -$184.42M(-13.0%) |
| Dec 2024 | -$154.53M(+68.8%) | -$25.72M(+45.1%) | -$163.18M(+26.3%) |
| Sep 2024 | - | -$46.82M(-61.5%) | -$221.49M(+28.9%) |
| Jun 2024 | - | -$28.99M(+53.0%) | -$311.34M(+22.6%) |
| Mar 2024 | - | -$61.65M(+26.6%) | -$402.38M(+21.9%) |
| Dec 2023 | -$495.13M(+19.8%) | -$84.03M(+38.5%) | -$515.42M(+13.4%) |
| Sep 2023 | - | -$136.68M(-13.9%) | -$595.01M(+2.6%) |
| Jun 2023 | - | -$120.03M(+31.3%) | -$610.92M(+4.4%) |
| Mar 2023 | - | -$174.68M(-6.8%) | -$639.17M(-7.8%) |
| Dec 2022 | -$617.33M(+15.6%) | -$163.63M(-7.2%) | -$593.13M(-14.4%) |
| Sep 2022 | - | -$152.58M(-2.9%) | -$518.52M(-5.0%) |
| Jun 2022 | - | -$148.28M(-15.3%) | -$493.66M(+8.4%) |
| Mar 2022 | - | -$128.64M(-44.5%) | -$539.22M(-0.8%) |
| Dec 2021 | -$731.27M(-134.2%) | -$89.02M(+30.3%) | -$534.78M(-69.6%) |
| Sep 2021 | - | -$127.72M(+34.1%) | -$315.36M(+0.5%) |
| Jun 2021 | - | -$193.84M(-56.1%) | -$316.87M(-32.9%) |
| Mar 2021 | - | -$124.20M(-195.2%) | -$238.42M(-12.0%) |
| Dec 2020 | -$312.23M | $130.40M(+200.9%) | -$212.87M(+52.6%) |
| Sep 2020 | - | -$129.24M(-12.0%) | -$448.99M(-15.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$115.39M(-17.0%) | -$389.56M(-15.4%) |
| Mar 2020 | - | -$98.64M(+6.7%) | -$337.53M(-17.4%) |
| Dec 2019 | -$298.83M(-139.1%) | -$105.72M(-51.5%) | -$287.42M(-31.3%) |
| Sep 2019 | - | -$69.80M(-10.2%) | -$218.89M(-18.4%) |
| Jun 2019 | - | -$63.35M(-30.5%) | -$184.89M(-52.1%) |
| Mar 2019 | - | -$48.54M(-30.5%) | -$121.54M(-29.0%) |
| Dec 2018 | -$124.99M(-146.9%) | -$37.20M(-3.9%) | -$94.23M(-65.2%) |
| Sep 2018 | - | -$35.80M(-68.7%) | -$57.03M(-26.9%) |
| Mar 2018 | - | -$21.23M(-83.2%) | -$44.95M(-14.4%) |
| Dec 2017 | -$50.63M(-86.7%) | - | - |
| Sep 2017 | - | -$11.59M(+4.5%) | -$39.30M(-12.5%) |
| Jun 2017 | - | -$12.13M(-34.0%) | -$34.94M(-53.2%) |
| Mar 2017 | - | -$9.05M(-38.8%) | -$22.81M(-65.8%) |
| Dec 2016 | -$27.12M(-35.0%) | -$6.52M(+9.9%) | -$13.76M(+3.1%) |
| Sep 2016 | - | -$7.23M(-3.9%) | -$14.20M(-17.1%) |
| Dec 2015 | -$20.09M(-78.0%) | -$6.96M(-35.0%) | -$12.12M(-50.2%) |
| Sep 2015 | - | -$5.16M(-77.0%) | -$8.07M(-44.6%) |
| Dec 2014 | -$11.29M(-180.6%) | -$2.91M(-9.3%) | -$5.58M(-109.3%) |
| Sep 2014 | - | -$2.67M | -$2.67M |
| Dec 2013 | -$4.02M | - | - |
FAQ
- What is Apellis Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Apellis Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Apellis Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Apellis Pharmaceuticals, Inc.?
- What is Apellis Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Apellis Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of APLS is -$154.53M
What is the all-time high annual EBITDA for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high annual EBITDA is -$4.02M
What is Apellis Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, APLS annual EBITDA has changed by +$340.60M (+68.79%)
What is Apellis Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of APLS is -$32.84M
What is the all-time high quarterly EBITDA for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high quarterly EBITDA is $130.40M
What is Apellis Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, APLS quarterly EBITDA has changed by -$3.85M (-13.26%)
What is Apellis Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of APLS is -$188.26M
What is the all-time high TTM EBITDA for Apellis Pharmaceuticals, Inc.?
Apellis Pharmaceuticals, Inc. all-time high TTM EBITDA is -$2.67M
What is Apellis Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, APLS TTM EBITDA has changed by +$123.08M (+39.53%)